The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

The most common adverse events were headache (35%), nausea, diarrhoea and nasopharyngitis (all 25%). Minor mean weight gain was found during the study, which did not appear to be dose-related.

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

The most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure, while the most common nonocular side effects included ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, ...

The most common side effects of Opzelura in clinical trials were application site acne, application site pruritus, nasopharyngitis (common cold), headache, urinary tract infection, application ...

Brensocatib was generally well tolerated. The most common treatment-emergent adverse events reported were COVID-19, headache, nasopharyngitis, and cough. “Brensocatib has the potential to ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

while the most common nonocular side effects included nasopharyngitis, anemia, nausea, and cough. "I am excited to offer Susvimo to my patients living with diabetic macular edema who want an ...